CN113490511B - 用于治疗狼疮的抗cd6抗体组合物和方法 - Google Patents

用于治疗狼疮的抗cd6抗体组合物和方法 Download PDF

Info

Publication number
CN113490511B
CN113490511B CN202080016831.1A CN202080016831A CN113490511B CN 113490511 B CN113490511 B CN 113490511B CN 202080016831 A CN202080016831 A CN 202080016831A CN 113490511 B CN113490511 B CN 113490511B
Authority
CN
China
Prior art keywords
alcam
subject
soluble
sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080016831.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113490511A (zh
Inventor
S·康纳利
K·波鲁
C·莫汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Houston system university
Iquiriham Co ltd
Original Assignee
Houston system university
Iquiriham Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Houston system university, Iquiriham Co ltd filed Critical Houston system university
Publication of CN113490511A publication Critical patent/CN113490511A/zh
Application granted granted Critical
Publication of CN113490511B publication Critical patent/CN113490511B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080016831.1A 2019-02-26 2020-02-26 用于治疗狼疮的抗cd6抗体组合物和方法 Active CN113490511B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810628P 2019-02-26 2019-02-26
US62/810,628 2019-02-26
US201962933294P 2019-11-08 2019-11-08
US62/933,294 2019-11-08
PCT/US2020/019990 WO2020176682A1 (en) 2019-02-26 2020-02-26 Anti-cd6 antibody compositions and methods for treating lupus

Publications (2)

Publication Number Publication Date
CN113490511A CN113490511A (zh) 2021-10-08
CN113490511B true CN113490511B (zh) 2024-07-09

Family

ID=70009403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080016831.1A Active CN113490511B (zh) 2019-02-26 2020-02-26 用于治疗狼疮的抗cd6抗体组合物和方法

Country Status (12)

Country Link
US (1) US20220143140A1 (https=)
EP (1) EP3930751A1 (https=)
JP (1) JP2022521973A (https=)
CN (1) CN113490511B (https=)
AU (1) AU2020229830A1 (https=)
BR (1) BR112021016967A2 (https=)
CA (1) CA3131299A1 (https=)
MX (1) MX2021010283A (https=)
PH (1) PH12021551994A1 (https=)
SG (1) SG11202109118XA (https=)
WO (1) WO2020176682A1 (https=)
ZA (1) ZA202107077B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
JP2023552762A (ja) * 2020-12-04 2023-12-19 エクイリウム，インコーポレイテッド Ｃｄ６ｈｉｇｈ細胞を選択的に標的化してｔｅｆｆ細胞の活性を低下する方法
EP4533094A4 (en) * 2022-05-25 2026-05-06 Univ Houston System Methods and systems for risk stratification and management of bladder cancer
TWI869873B (zh) * 2023-06-05 2025-01-11 中國醫藥大學 一種檢測一個體罹患單純復發性風濕病的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372215B1 (en) * 1997-03-03 2002-04-16 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
JP5900489B2 (ja) * 2011-03-25 2016-04-06 コニカミノルタ株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
BR112013033988B1 (pt) * 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
AU2013229786B2 (en) * 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015107501A1 (en) * 2014-01-20 2015-07-23 Ghiggeri Gian Marco In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
EP3439658B1 (en) * 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
WO2017214452A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
ES2991182T3 (es) * 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372215B1 (en) * 1997-03-03 2002-04-16 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab;Usha Bughani;Plos One;第1-29页 *

Also Published As

Publication number Publication date
SG11202109118XA (en) 2021-09-29
PH12021551994A1 (en) 2022-08-15
ZA202107077B (en) 2023-07-26
JP2022521973A (ja) 2022-04-13
CN113490511A (zh) 2021-10-08
CA3131299A1 (en) 2020-09-03
BR112021016967A2 (pt) 2021-11-23
MX2021010283A (es) 2021-09-30
EP3930751A1 (en) 2022-01-05
AU2020229830A1 (en) 2021-09-16
WO2020176682A1 (en) 2020-09-03
US20220143140A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
CN113490511B (zh) 用于治疗狼疮的抗cd6抗体组合物和方法
US10202454B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
KR102223464B1 (ko) Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
TW202300168A (zh) Il-8相關疾病之治療用或預防用組成物
CN104870013A (zh) 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
US12258409B2 (en) Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies
JP2011514318A (ja) カドヘリン１１（ｃｄｈ１１）アンタゴニストの使用方法
AU2023275542A1 (en) Methods for the treatment of kidney diseases or disorders
EP3062817B1 (en) Il-3 blockade in systemic lupus erythematosus and multiple sclerosis
HK40052994B (zh) 用於治疗狼疮的抗cd6抗体组合物和方法
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
HK40052994A (en) Anti-cd6 antibody compositions and methods for treating lupus
BR112020016400A2 (pt) Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052994

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant